NIM
CRSP icon

NEOS Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

NEOS Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,231
Closed -$639K – 605
2024
Q4 		$639K Sell
16,231
-7,092
-30% -$335K 0.02% 475
2024
Q3 		$1.1M Buy
23,323
+5,387
+30% +$273K 0.03% 355
2024
Q2 		$969K Buy
17,936
+10,450
+140% +$604K 0.04% 334
2024
Q1 		$510K Buy
7,486
+220
+3% +$15.7K 0.03% 379
2023
Q4 		$455K Buy
+7,266
New +$402K 0.04% 302

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NEOS Investment Management's CRSP Position: Q1 2025 in Review

NEOS Investment Management sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 16,231 shares — an estimated $639K sold.

NEOS Investment Management first reported a position in CRSP in Q4 2023 and held it in 5 quarters. The position peaked at $1.1M in Q3 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • NEOS Investment Management reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • NEOS Investment Management sold 16,231 CRISPR Therapeutics shares in Q1 2025, an estimated $639K.
  • NEOS Investment Management first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 5 quarters.
  • NEOS Investment Management's CRISPR Therapeutics position peaked at $1.1M in Q3 2024.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on NEOS Investment Management's 13F filing for Q1 2025, filed 15 May 2025.